
Best Practice for Smoking Cessation: Pharmacotherapy

Emma Dean

Acting Population Health and Health Promotion Coordinator
Lead Pharmacist- Smokefree

AlfredHealth



Why is it so hard to quit?


People who smoke aren't weak nor are they simply making a bad lifestyle choice.

Smoking is a complex process made up of:

- Nicotine dependence
- Behavioural connections
- Psychological connections

Nicotine

- **Short half-life (average 2 hours)**
 - In some individuals as short as 20-40minutes
- **What it does:**
 - Dependence, short term relief of anxiety and low mood, increased arousal and concentration
 - Minor haemodynamic effects: increased HR, transient increase in BP
- **What it doesn't do:**
 - Not classed as carcinogen by IARC
 - Does not cause cardiovascular disease
 - Does not cause lung damage
- **Plays a small role in human disease- 'people smoke for nicotine, but die from smoke'**



Nicotine Dependence

- **Chronic medical condition with multiple cycles of relapse and remission**
 - Relapsed smokers need to be re-engaged and assisted through repeated quit attempts
- **Under recognised by health professionals**
- **Assessment is important**
- **Time to first cigarette a reliable indicator**

Questions	Response coding	Score	Dependence score
How soon after you wake do you smoke your first cigarette?	Within 5 minutes = 3 5 – 30 minutes = 2 31 – 60 minutes = 1 Over 60 minutes = 0		≤ 2 = very low 3 = low 4 = moderate 5+ = high
How many cigarettes a day do you smoke?	10 or less = 0 11 – 20 = 1 21 – 30 = 2 31 or more = 3		
	Fagerstrom Score	/ 6	

Nicotine withdrawal syndrome

- **Symptoms begin within hours of quitting**
- **Duration and severity of symptoms are highly variable among individuals**
 - Generally worst in first 24-48 hours
- **Symptoms are usually alleviated in 2-4 weeks**
 - Dizziness, insomnia, restlessness, difficulty concentrating, irritability, increase appetite, mood changes

Other mechanisms underlying smoking

Psychological connection

- smoking is related to how clients feel, their moods and emotions
- commonly draw a connection between smoking and stress relief, feelings of comfort and relaxation

Behavioural connections

- behaviours that are closely linked to their smoking
- connections tend to be strong and have built up over many years

Okay so what can we do?



Importance of brief intervention



Brief advice from a healthcare professional prompts people to quit

NNT 1 in 33

Increases long-term abstinence rates by 1-3 percentage points (above unassisted quit rates, which are around 2-3%)

Best practice for smoking cessation

- **3%- 5% people who smoke, successfully quit cold turkey**
- **Interventions that **combine** pharmacotherapy and behavioural support increase smoking cessation success in a wide range of settings and populations**
- **Need to encourage people who smoke to use both pharmacotherapy and behavioural support**

Pharmacotherapy


- **Nicotine replacement therapy (NRT)**
 - Transdermal- patches
 - Intermittent- lozenges, mouthspray, gum and inhalator
- **Bupropion (Zyban®)**
- **Varenicline (Champix®)**

Nicotine replacement therapy

- **Increases quit rates by 50-70% compared to placebo**
- **Reduces cravings and minimises withdrawal symptoms**
- **Safety and efficacy profile**
 - Does not produce dramatic surges in blood levels
 - Minimal addictive potential
 - No serious side effects, usually minor and formulation related
- **Best result = NRT (minimum 8/52) + behavioural advice + follow up**
- **No evidence for weaning the patch**



Plasma nicotine levels- single dose



Combination Therapy

Patch + Intermittent

Patch: Steady protection (long acting and slow onset) to control baseline cravings

Intermittent: Quicker and more flexible relief
If possible use in anticipation of smoking trigger

- Adverse effect profile similar to mono-therapy




Nicotine patch

- **Slow skin absorption – takes several hours to reach steady state (depends on brand)**
 - If removed overnight, substantial nicotine levels are reached within 3 hours after a new patch is applied
- **Produces relatively constant withdrawal relief over 24 hours**
- **Can be started 2 weeks before setting ‘quit date’ - increases quit rates by 35% (compared to traditional quit day application)**
- **Continue to use patch after a lapse- 4-5 times more likely to be abstinent at end of treatment period**

Fant 2000

Mendelsohn 2013



Nicotine patch

- **Apply to clean, hairless skin**
- **Hold firmly in place for 20 seconds after application to assist adhesion**
- **Swimming & showering ok after an hour**
- **Tape around edges if lifting**
- **Rotate patch around body**
- **Sleep disturbance (vivid dreaming) common → if disrupting daily activities, put patch on in AM and remove PM, could try lower dose patch; does decrease over time; consider caffeine reduction**
- **< 10% have skin irritation (usually due to adhesive) → cortisone cream may be helpful**
- **Different brands have different properties and deliver blood nicotine levels about half as those from smoking**

Nicotine gum

- **Nicotine is readily absorbed from oral mucosa membranes**
- **Two strengths- 2mg & 4mg gum**
- **Best to start immediately upon waking**
- **Use liberally (no greater than 1 piece/hour)**
- **'Chew and park' method – chew every 2 seconds for approximately 30minutes**
- **Adverse effects- nausea, hiccups, bloating**




Nicotine lozenge



- **Nicotine is readily absorbed from oral mucosa membranes**
- **Strengths**
 - 2mg & 4mg lozenge (Nicorette Cooldrops®)
 - 1.5mg & 4mg mini lozenge (Nicabate Mini lozenges®)
- **Use liberally to suppress cravings/urges to smoke**
- **Lozenge should be placed in the mouth and moved from one side to the other until completely dissolved**
 - Should not be chewed, sucked or swallowed whole
- **Adverse effects- hiccups, nausea, flatulence & sensitive mouth**

Nicotine inhalator

- **Nicotine is readily absorbed from oral mucosa membranes**
- **Strength- 15mg/cartridge**
- **When used as a cigarette, taking 8 times as many puffs as when smoking, delivers about 1 mg of nicotine**
- **A cartridge will deliver the same amount of nicotine (1 mg), at a uniform release rate, for the first seven consecutive uses**
- **Designed to combine pharmacological and behavioural substitution (hand to mouth ritual)**
- **Patients can self-titrate to the level of nicotine they require to relieve cravings**
- **Adverse effects- hiccups, sore throat, heartburn**



Nicotine spray

- **Nicotine is absorbed through oral mucosa membranes**
- **Oral spray form means that nicotine is administered instantaneously**
- **Strength- 1mg/dose (150 doses per device)**
- **Use liberally to suppress cravings/urges to smoke**
- **Priming is needed for first time use and if not used greater than 2 days**
- **Adverse effects- nausea, mouth irritation, taste disturbances, hiccups, indigestion**



Troubleshooting

- **Misconceptions can lead to inadequate dose**
- **Side effects of NRT can be nicotine withdrawal (or incorrect use)**
- **Common to underdose on NRT (overdosing is rare)**
- **Nicotine from all the intermittent products is absorbed through the buccal mucosa → concurrent eating and drinking should be discouraged.**
- **Being nil oral is not a contraindication; avoid gum pre-op as can increase intra-gastric volumes**



How to boost patient compliance...

- **Concerns about safety**
 - NRT is always safer than smoking
 - Safety profile- does not cause cancer, lung disease, cardiovascular disease
- **Concerns about the addictiveness of NRT**
 - Minimal addictive potential
- **Lack of confidence in efficacy**
 - Proven effective (significant increases chances of quitting); minimises nicotine withdrawal symptoms
- **Not using enough**
 - More effective when dose titrated according to response
- **Stopping NRT too early**
 - Needs to be taken for long enough to start to address other drivers of smoking
 - Best not to cease until patient can resist cravings in situations

How to boost patient compliance....

- **NRT is not working**
 - May require increased dose (combination therapy, more doses of intermittent, second patch)
 - Are the products being used correctly/
 - Consider change to varenicline
- **Side effects**
 - Decrease over time
 - Are the products being used correctly?
- **Cost**
 - NRT cost vs. cigarettes (and ongoing smoking- financial & health)

Varenicline (Champix)



Varenicline- Troubleshooting

- **Nausea**
 - Always take with food
 - Increase fluid intake, 10 glasses water /day if clinically appropriate
- **Insomnia – bring evening dose forward**
- **Renal impairment – reduced dose 1mg per day**
- **If not tolerating for any reason consider reduced dose**

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

Robert M Anthenelli, Neal L Benowitz, Robert West, Lisa St Aubin, Thomas McRae, David Lawrence, John Ascher, Cristina Russ, Alok Krishen, A Eden Evins

8058 Treatment-seeking smokers

History of psychiatric disorders (N=4074)
Primary affective disorders (70%), anxiety disorders (19%), psychotic disorders (9.5%), personality disorders (0.6%)

Without a history of psychiatric disorders (N=3984)

Randomly allocated to one of four treatment arms

varenicline (1 mg twice daily)

bupropion SR (150 mg twice daily),

transdermal nicotine patch (21 mg with taper)

placebo

Cohort	CHAMPIX	Bupropion	NRT Patch (NQuitin®)	Placebo
Psychiatric n= 4074	67/1026 6.5%	68/1017 6.7%	53/1016 5.2%	50/1015 4.9%
Non-Psychiatric n= 3984	13/990 1.3%	22/989 2.2%	25/1006 2.5%	24/999 2.4%

- **The rate of neuro-psychiatric adverse events (AEs) was similar (not significantly different) across the four treatment groups**
(i.e. no indication that varenicline or bupropion are associated with these AEs anymore than nicotine patch or placebo)
- **More AEs in the psychiatric cohort compared with the non-psychiatric cohort**
(i.e. people with mental illness were more likely to experience AEs, regardless of which medicine they were using)

Drug Interactions

Many interactions identified; varying clinical significance

Chemicals in tobacco smoke can interact by two mechanisms

- *Pharmacokinetic*- usually poly-carbons not nicotine stimulation of hepatic enzymes
antipsychotics (clozapine, olanzapine), warfarin & caffeine
- *Pharmacodynamic*- largely due to nicotine alter the expected response or actions of other drugs
beta-blockers, insulin

Dose adjustments may be required and based on clinical presentation and according to medical review

Emma Dean
Acting Population Health and Health Promotion Coordinator
Lead Pharmacist- Smokefree
e.dean@alfred.org.au